'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer

被引：6
|
作者：
Voskoboynik, Mark [1 ,2 ]
Staffurth, John [3 ]
Malik, Zafar [4 ]
Sweeney, Christopher [5 ,6 ]
Chowdhury, Simon [1 ,2 ]
机构：
[1] Guys Hosp, Dept Med Oncol, London SE1 9RT, England
[2] Sarah Cannon Res Inst UK, London, England
[3] Cardiff Univ, Inst Canc & Genet, Velindre Canc Ctr, Cardiff, S Glam, Wales
[4] Clatterbridge Canc Ctr, Bebington, Wirral, England
[5] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[6] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2014年 / 14卷 / 11期
关键词：
CHAARTED; docetaxel; hormone sensitive; metastatic prostate cancer; Sweeney; MITOXANTRONE PLUS PREDNISONE; INCREASED SURVIVAL; OPEN-LABEL; CHEMOTHERAPY; ABIRATERONE; ENZALUTAMIDE; PHASE-3; TRIAL;
D O I：
10.1586/14737140.2014.971112
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Docetaxel has an established role in the treatment of metastatic castrate-resistant prostate cancer. A number of recent treatments have been shown to improve the survival outcomes for this group of patients and many with improved toxicity profiles, bringing the role of docetaxel into question. We discuss the results and implications of the CHAARTED study that demonstrated a significant improvement in overall survival with docetaxel in metastatic hormone-sensitive prostate cancer. © Informa UK, Ltd.
引用
收藏
页码：1253 / 1256
页数：4
相关论文
共 50 条
  • [41] Charting a course in metastatic castration-sensitive prostate cancer
    Madan, Ravi A.
    Dahut, William L.
    NATURE REVIEWS UROLOGY, 2015, 12 (07) : 368 - 369
  • [42] Charting a course in metastatic castration-sensitive prostate cancer
    Ravi A. Madan
    William L. Dahut
    Nature Reviews Urology, 2015, 12 : 368 - 369
  • [43] Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer
    Michael T. Schweizer
    Roman Gulati
    Elahe A. Mostaghel
    Peter S. Nelson
    R. Bruce Montgomery
    Evan Y. Yu
    Heather H. Cheng
    Medical Oncology, 2016, 33
  • [44] Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer
    Schweizer, Michael T.
    Gulati, Roman
    Mostaghel, Elahe A.
    Nelson, Peter S.
    Montgomery, R. Bruce
    Yu, Evan Y.
    Cheng, Heather H.
    MEDICAL ONCOLOGY, 2016, 33 (07)
  • [45] Cytoreductive prostate cryoablation and metronomic cyclophosphamide for metastatic hormone-sensitive prostate cancer
    Li, Yonghong
    Wang, Ning
    Zhao, Diwei
    Wang, Jun
    Jiang, Lijuan
    Wang, Yanjun
    Chen, Dong
    Wu, Zhiming
    Zhou, Fangjian
    Yang, Zhenyu
    FUTURE ONCOLOGY, 2022, 18 (19) : 2373 - 2380
  • [46] Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy
    Yanagisawa, Takafumi
    Hata, Kenichi
    Narita, Shintaro
    Hatakeyama, Shingo
    Mori, Keiichiro
    Yata, Yuji
    Sano, Takayuki
    Otsuka, Takashi
    Hara, Shuhei
    Miyajima, Keiichiro
    Enei, Yuki
    Fukuokaya, Wataru
    Nakazono, Minoru
    Matsukawa, Akihiro
    Miki, Jun
    Habuchi, Tomonori
    Ohyama, Chikara
    Shariat, Shahrokh F.
    Kimura, Takahiro
    PROSTATE, 2023, 83 (06): : 563 - 571
  • [47] Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever
    Tsao, Che-Kai
    Galsky, Matthew D.
    Oh, William K.
    EUROPEAN UROLOGY, 2016, 70 (05) : 707 - +
  • [48] Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra
    Fizazi, K.
    Jenkins, C.
    Tannock, I. F.
    ANNALS OF ONCOLOGY, 2015, 26 (08) : 1660 - 1667
  • [49] Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy
    Yanagiswawa, T.
    Hata, K.
    Narita, S.
    Hatakeyama, S.
    Mori, K.
    Yata, Y.
    Sano, T.
    Otsuka, T.
    Hara, S.
    Miyajima, K.
    Enei, Y.
    Fukuokaya, W.
    Nakazono, M.
    Matsukawa, A.
    Miki, J.
    Habuchi, T.
    Ohyama, C.
    Shariat, S. F.
    Kimura, T.
    EUROPEAN UROLOGY, 2023, 83
  • [50] Cost-effectiveness of docetaxel in high-volume hormone-sensitive metastatic prostate cancer
    Beca, Jaclyn
    Majeed, Habeeb
    Chan, Kelvin K. W.
    Hotte, Sebastian J.
    Loblaw, Andrew
    Hoch, Jeffrey S.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2019, 13 (12): : 396 - 403
12345